Obsidian Will Present Amsoki-cel Data in November 2026

The biotech firm plans to report clinical results for its engineered cell therapy at the upcoming SITC meeting.

Updated on Oct. 2, 2026 in Biotech

Isometric editorial illustration showing a sterile culture flask and glass pipette, representing advanced cellular therapy research. — Obsidian Therapeutics will present phase 2 clinical efficacy data for its engineered amsoki-cel cell therapy at the Society for Immunotherapy of Cancer meeting in November 2026. AI Illustration. Upload story photo >

Live Poll

Is now a good time to increase investment in experimental cancer therapies like cell treatments?

Obsidian Therapeutics announced it will present updated safety and efficacy data for its engineered tumor-infiltrating lymphocyte (TIL) therapy, amsoki-cel, on November 7, 2026. The announcement details findings from a clinical efficacy update involving 15 patients treated at the recommended phase 2 dose.

Why it matters

Amsoki-cel represents a research-stage approach to treating advanced melanoma by modifying immune cells to improve persistence and activity. The upcoming presentation at the Society for Immunotherapy of Cancer (SITC) meeting will provide the first look at the phase 2 registration-enabling cohort of the Agni-01 trial.

Amsoki-cel is engineered with membrane-bound IL15, a cytokine protein that supports immune cell survival and proliferation, designed to enhance the efficacy of traditional TIL therapies. Clinical findings are cataloged in abstract 566 for safety and efficacy and abstract 570 for the trial-in-progress.

The players

Obsidian Therapeutics

A Cambridge-based biotechnology company focused on developing engineered TIL cell therapies through protein-regulation technology.

The details

Obsidian Therapeutics utilizes protein-regulation technology to create engineered TILs, which are immune cells collected from a patient's own tumor that are grown in the lab and returned to the body. By arming these cells with membrane-bound IL15, the therapy aims to overcome the immunosuppressive tumor microenvironment that typically exhausts T-cells. This research-stage mechanism is currently being evaluated in the Agni-01 clinical trial to establish the therapy as a viable option for advanced melanoma.

November 4-8, 2026: The SITC 2026 Annual Meeting takes place in Phoenix, AZ.
November 7, 2026: Obsidian Therapeutics will present clinical data via poster presentations.

The Tech Race

The study sits within the broader landscape of TIL therapy development and acts as a pivotal milestone for Obsidian Therapeutics. This upcoming data presentation marks a critical update for the Agni-01 trial as it moves toward registration-enabling results.

Amsoki-cel remains in the research-stage and is not currently available for patient use or clinical prescription. Data presented in November will help determine whether the therapy progresses toward regulatory approval as a future treatment option for advanced melanoma.

The takeaway

The November SITC presentation will clarify whether this engineered TIL approach meets the criteria required for further registration steps. Observers should track the efficacy data from the 15-patient cohort to gauge the viability of IL15-armed cells in solid tumor treatments.